Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences, Inc. (NBIX) 最新ニュース

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Zacks Investment Research

Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus

Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Zacks Investment Research

Neurocrine (NBIX) Reports Q1 Earnings: What Key Metrics Have to Say

Zacks Investment Research

Neurocrine Biosciences (NBIX) Q1 Earnings Miss Estimates

Zacks Investment Research

Curious about Neurocrine (NBIX) Q1 Performance? Explore Wall Street Estimates for Key Metrics

Zacks Investment Research

Zoetis (ZTS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks Investment Research

Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth

Zacks Investment Research

Where Neurocrine Biosciences Stands With Analysts

Benzinga

Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform

Benzinga

In-Depth Examination Of 8 Analyst Recommendations For Neurocrine Biosciences

Benzinga

Decoding 8 Analyst Evaluations For Neurocrine Biosciences

Benzinga

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Zacks Investment Research

Is Invesco Biotechnology & Genome ETF (PBE) a Strong ETF Right Now?

Zacks Investment Research

Why This Teva Pharmaceutical Analyst Is Turning Bullish On The Austedo Franchise

Benzinga

Breaking Down Neurocrine Biosciences: 8 Analysts Share Their Views

Benzinga

AMLX vs. NBIX: Which Stock Should Value Investors Buy Now?

Zacks Investment Research

Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?

Zacks Investment Research

Unveiling 13 Analyst Insights On Neurocrine Biosciences

Benzinga

How Neurocrine (NBIX) Stock Stands Out in a Strong Industry

Zacks Investment Research

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)?

Zacks Investment Research

Neurocrine (NBIX) Soars 6.0%: Is Further Upside Left in the Stock?

Zacks Investment Research

Analyst Expectations for Neurocrine Biosciences's Future

Benzinga